In a multicenter cohort study, hs-cTnI and MPO, along with LVEF, were identified as predictors of cardiotoxicity risk in 78 breast cancer patients who received DOX and trastuzumab for 3 months. The gene discussed is TNNI3; the disease is breast cancer.